Skip to main content

Testing version — LOERadar is in active testing. Features and data may change.

Hub News Changes Search

LOERadar

FDA drug patent and exclusivity intelligence, assembled from public records.

Sponsored by

About Terms of Service Privacy Policy Log in

Attorney Advertising

© 2026 LOERadar · An informational research tool drawn from public records; it is not a law firm, does not provide legal advice, and its use does not create an attorney-client relationship.

RESERPINE AND HYDROCHLOROTHIAZIDE (HYDROCHLOROTHIAZIDE; RESERPINE) | LOERadar

Viewing data from:

RESERPINE AND HYDROCHLOROTHIAZIDE

ANDA

HYDROCHLOROTHIAZIDE; RESERPINE | A088200 | SANDOZ INC

1 strength0 unique patents0 unique exclusivities

Products (1)

#001 — 50MG;0.125MG

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Jan 31, 1984

No patent or exclusivity listings for this strength.